An update on Huntington's disease: From the gene to the clinic

Current Opinion in Neurology

Volumn 27, Issue 4, 2014, Pages 477-483

  Kim, Samuel D ^a,b   Fung, Victor S C ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

biomarker; Huntington's disease; neurodegeneration; premanifest Huntington's disease; prodromal Huntington's disease

Indexed keywords

BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; HUNTINGTIN; UBIDECARENONE;

BEHAVIOR; CLEARANCE; CLINICAL FEATURE; COGNITION; DISEASE COURSE; EXCITOTOXICITY; GENETIC TRANSCRIPTION; HUMAN; HUNTINGTON CHOREA; IMMUNOPATHOLOGY; MITOCHONDRION; MOTOR PERFORMANCE; MUTANT; NEUROIMAGING; NEUROPHYSIOLOGY; NONHUMAN; PALLIATIVE THERAPY; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN PROCESSING; REVIEW; TRANSCRANIAL MAGNETIC STIMULATION; GENETICS; HUNTINGTON DISEASE;

HUMANS; HUNTINGTON DISEASE;

EID: 84904065460     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000116     Document Type: Review

References (73)

1. MacDonald ME, Ambrose CM, Duyao MP, et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72:971-983.
2. Paulsen JS. Cognitive impairment in Huntington disease: diagnosis and treatment. Curr Neurol Neurosci Rep 2011; 11:474-483.
3. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996; 11:136-142.
4. Ross CA, Aylward EH, Wild EJ, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 2014; 10:204-216.
5. Chandra A, Johri A, Beal MF. Prospects for neuroprotective therapies in prodromal Huntington's disease. Mov Disord 2014; 29:285-293.
6. Stout JC, Paulsen JS, Queller S, et al. Neurocognitive signs in prodromal Huntington disease. Neuropsychology 2011; 25:1-14.
7. Harrington DL, Smith MM, Zhang Y, et al. Cognitive domains that predict time to diagnosis in prodromal Huntington disease. J Neurol Neurosurg Psychiatry 2012; 83:612-619.
8. Paulsen JS, Smith MM, Long JD. Cognitive decline in prodromal Huntington disease: implications for clinical trials. J Neurol Neurosurg Psychiatry 2013; 84:1233-1239.
9. Mickes L, Wixted JT, Peavy GM, et al. Difficulty modifying a sustained motor response in prodromal Huntington's disease. J Clin Exp Neuropsychol 2013; 35:35-40.
10. Long JD, Paulsen JS, Marder K, et al. Tracking motor impairments in the progression of Huntington's disease. Mov Disord 2013; 23:311-319.
11. Weir DW, Sturrock A, Leavitt BR. Development of biomarkers for Huntington's disease. Lancet Neurol 2011; 10:573-590.
12. Tabrizi SJ, Reilmann R, Roos RA, et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 2012; 11:42-53.
13. Tabrizi SJ, Scahill RI, Owen G, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observatonal data. Lancet Neurol 2013; 12:637-649.
14. Scahill RI, Hobbs NZ, Say MJ, et al. Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy. Hum Brain Mapp 2011; 34:519-529.
15. Matsui JT, Vaidya JG, Johnson HJ, et al. Diffusion weighted imaging of prefrontal cortex in prodromal Huntington's disease. Hum Brain Mapp 2013; 35:1562-1573.
16. Tang CC, Feigin A, Ma Y, et al. Metabolic network as a progression biomarker of premanifest Huntington's disease. J Clin Invest 2013; 123:4076-4088.
17. Hua J, Unschuld PG, Margolis RL, et al. Elevated arteriolar cerebral blood volume in prodromal Huntington's disease. Mov Disord 2013; 29:396-401.
18. Philpott AL, Fitzgerald PB, Cummins TD, Georgiou-Karistianis N. Transcranial magnetic stimulation as a tool for understanding neurophysiology in Huntington's disease: a review. Neurosci Biobehav Rev 2013; 37:1420-1433.
19. Walker FO. Huntington's disease. Lancet 2007; 369:218-228.
20. Takano H, Cancel G, Ikeuchi T, et al. Close associations between prevalences of dominantly inherited spinocerebellar ataxias with CAG-repeat expansions and frequencies of large normal CAG alleles in Japanese and Caucasian populations. Am J Hum Genet 1998; 63:1060-1066.
21. Wright HH, Still CN, Abramson RK. Huntington's disease in black kindreds in South Carolina. Arch Neurol 1981; 38:412-414.
22. Myers R, Sax D, Schoenfeld M, et al. Late onset of Huntington's disease. J Neurol Neurosurg Psychiatry 1985; 48:530-534.
23. Roos RA. Huntington's disease: a clinical review. Orphanet J Rare Dis 2010; 5:40.
24. Wexler NS, Lorimer J, Porter J, et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci USA 2004; 101:3498-3503.
25. Byars JA, Beglinger LJ, Moser DJ, et al. Substance abuse may be a risk factor for earlier onset of Huntington disease. J Neurol 2012; 259:1824-1831.
26. James CM, Houlihan GD, Snell RG, et al. Late-onset Huntington's disease: a clinical and molecular study. Age Ageing 1994; 23:445-448.
27. Lipe H, Bird T. Late onset Huntington disease: clinical and genetic characteristics of 34 cases. J Neurol Sci 2009; 276:159-162.
28. Koutsis G, Karadima G, Kladi A, et al. Huntington's disease: diagnostic and prognostic considerations. Parkinsonism Relat Disord 2014. (in press).
29. McCusker EA, Gunn DG, Epping EA, et al. Unawareness of motor phenoconversion in Huntington disease. Neurology 2013; 81:1141-1147.
30. Ha AD, Fung VS. Huntington's disease. Curr Opin Neurol 2012; 25:491-498.
31. Shao J, Diamond MI. Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum Mol Genet 2007; 16 (Spect No. 2):R115-R123.
32. Tobin AJ, Signer ER. Huntington's disease: the challenge for cell biologists. Trends Cell Biol 2000; 10:531-536.
33. Sánchez I, Mahlke C, Yuan J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 2003; 421:373-379.
34. Lu B, Nagappan G, Guan X, et al. BDNF-based synaptic repair as a diseasemodifying strategy for neurodegenerative diseases. Nat Rev Neurosci 2013; 14:401-416.
35. Zuccato C, Marullo M, Vitali B, et al. Brain-derived neurotrophic factor in patients with Huntington's disease. PLoS One 2011; 6:e22966.
36. Xie Y, Hayden MR, Xu B. BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice. J Neurosci 2010; 30: 14708-14718.
37. Jiang M, Wang J, Fu J, et al. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat Med 2012; 18:153-158.
38. Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 2010; 90:905-981.
39. Mielcarek M, Landles C, Weiss A, et al. HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration. PLoS Biol 2013; 11:e1001717.
40. Paul BD, Sbodio JI, Xu R, et al. Cystathionine g lyase deficiency mediates neurodegeneration in Huntington's disease. Nature 2014; 509:96-100.
41. Cui L, Jeong H, Borovecki F, et al. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006; 127:59-69.
42. Shirendeb U, Reddy AP, Manczak M, et al. Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. Hum Mol Genet 2011; 20:1438-1455.
43. Shirendeb UP, Calkins MJ, Manczak M, et al. Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease. Hum Mol Genet 2012; 21:406-420.
44. Orr AL, Li S, Wang C-E, et al. N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. Journal Neurosci 2008; 28:2783-2792.
45. Ali NJ, Levine MS. Changes in expression of N-methyl-D-aspartate receptor subunits occur early in the R6/2 mouse model of Huntington's disease. Dev Neurosci 2006; 28:230-238.
46. Raymond LA, André VM, Cepeda C, et al. Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. Neuroscience 2011; 198:252-273.
47. Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000; 101:57-66.
48. Safren N, El Ayadi A, Chang L, et al. Ubiquilin-1 overexpression increases the lifespan and delays accumulation of Huntingtin aggregates in the R6/2 mouse model of Huntington's disease. PLoS One 2014; 9:e87513.
49. Sathasivam K, Neueder A, Gipson TA, et al. Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc Natl Acad Sci USA 2013; 110:2366-2370.
50. Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011; 10:83-98.
51. Thompson LM, Aiken CT, Kaltenbach LS, et al. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J Cell Biol 2009; 187:1083-1099.
52. Di Pardo A, Maglione V, Alpaugh M, et al. Ganglioside GM1induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice. Proc Natl Acad Sci USA 2012; 109:3528-3533.
53. Young FB, Butland SL, Sanders SS, et al. Putting proteins in their place: palmitoylation in Huntington disease and other neuropsychiatric diseases. Prog Neurobiol 2012; 97:220-238.
54. Singaraja RR, Huang K, Sanders SS, et al. Altered palmitoylation and neuropathological deficits in mice lacking HIP14. Hum Mol Genet 2011; 20:3899-3909.
55. Sutton LM, Sanders SS, Butland SL, et al. Hip14l-deficient mice develop neuropathological and behavioural features of Huntington disease. Hum Mol Genet 2013; 22:452-465.
56. Weiss A, Träger U, Wild EJ, et al. Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression. J Clin Invest 2012; 122: 3731-3736.
57. Dalrymple A, Wild EJ, Joubert R, et al. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J Proteome Res 2007; 6:2833-2840.
58. Kwan W, Magnusson A, Chou A, et al. Bone marrow transplantation confers modest benefits in mouse models of Huntington's disease. J Neurosci 2012; 32:133-142.
59. Zwilling D, Huang S-Y, Sathyasaikumar KV, et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 2011; 145:863-874.
60. Träger U, Andre R, Lahiri N, et al. HTT-lowering reverses Huntington's disease immune dysfunction caused by NFkB pathway dysregulation. Brain 2014; 137:819-833.
61. Cudkowicz M, McDermott M, Kieburtz K. Coenzyme Q10 in Huntington's Disease (HD) [Internet]. Available from: http://clinicaltrials.gov/show/ NCT00608881.
62. Group HS. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001; 57:397-404.
63. Hersch SM, Schifitto G, Rosas D. Creatine Safety, Tolerability, and Efficacy in Huntington's Disease (CREST-E) [Internet]. Available from: https://clinicaltrials. gov/ct2/show/NCT00712426.
64. Rosas HD, Doros G, Gevorkian S, et al. PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease. Neurology 2014; 82:850-857.
65. McCusker EA, Myers RH. Feasibility of Huntington disease trials in the disease prodrome. Neurology 2014; 82:824-825.
66. Sah DW, Aronin N. Oligonucleotide therapeutic approaches for Huntington disease. J Clin Invest 2011; 121:500-507.
67. Harper SQ, Staber PD, He X, et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci USA 2005; 102:5820-5825.
68. DiFiglia M, Sena-Esteves M, Chase K, et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci USA 2007; 104: 17204-17209.
69. Drouet V, Perrin V, Hassig R, et al. Sustained effects of nonallele-specific Huntingtin silencing. Ann Neurol 2009; 65:276-285.
70. Kordasiewicz HB, Stanek LM, Wancewicz EV, et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 2012; 74:1031-1044.
71. Venuto CS, McGarry A, Ma Q, Kieburtz K. Pharmacologic approaches to the treatment of Huntington's disease. Mov Disord 2012; 27:31-41.
72. Nishi A, Kuroiwa M,Miller DB, et al. Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J Neurosci 2008; 28:10460-10471.
73. Ahmad R, Bourgeois S, Postnov A, et al. PET imaging shows loss of striatal PDE10A in patients with Huntington disease. Neurology 2014; 82:279-281.